Lorenza Landi

Research interests

Publications

• Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

  Cancer Discovery · 2023 · https://doi.org/10.1158/2159-8290.cd-22-1420

• Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy

  Journal for ImmunoTherapy of Cancer · 2021 · https://doi.org/10.1136/jitc-2021-002421

• First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status

  European Journal of Cancer · 2020 · https://doi.org/10.1016/j.ejca.2020.02.023

• Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer

  Journal for ImmunoTherapy of Cancer · 2019 · https://doi.org/10.1186/s40425-019-0793-8

• Crizotinib in MET -Deregulated or ROS1 -Rearranged Pretreated Non–Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial

  Clinical Cancer Research · 2019 · https://doi.org/10.1158/1078-0432.ccr-19-0994

• PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients

  British Journal of Cancer · 2014 · https://doi.org/10.1038/bjc.2014.555

• HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients

  British Journal of Cancer · 2013 · https://doi.org/10.1038/bjc.2013.4

Current projects

No projects listed.